Peptides for treatment of HIV infection
AssigneeAdvanced Immuni T, Inc.
InventorsCandace Pert, Michael Ruff
Life of this patent
Estimating the term…
Abstract
The HIV-1 envelope protein gp120 is toxic to rodent and human neurons by indirect mechanisms requiring accessory glial cells. Chemokines are known to block gp120 interactions with chemokine receptors on T cells, macrophanges, and microglia, thereby preventing viral infection. Gp120-induced neuronal killing in rat hippocampal cultures was partially or completely prevented by a specific short peptides related to chemokines, specially IKEYFTS (SEQ. ID NO: 2) and LESYT (SEQ. ID NO: 1). These peptides thus have use in the treatment of neurological degenerative diseases having symptoms associated with neuronal cell death.
Claims10
A peptide of the formula Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO:
- 1) or Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO:
- 2).
A pharmaceutical composition comprising as an active ingredient at least one peptide of the formula Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO:
- 1) or Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO:
- 2) or a pharmaceutically acceptable salt thereof.
A method for treating the symptoms caused by GP120 mediated neurotoxicity comprising administering to a person suffering from HIV infection a therapeutically effective amount of a peptide of formula Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO:
- 1) or Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO:
- 2).
A method for treating the symptoms caused by a loss of neurons resulting from Alzheimer's disease comprising administering a therapeutically effective amount of a peptide of formula Leu-Glu-Ser-Tyr-Thr (SEQ. ID NO:
- 1) or Ile-Lys-Glu-Tyr-Phe-Thr-Ser (SEQ. ID NO:
- 2).
Dependencies are inferred from the claim text.